ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

SAGE Sage Therapeutics Inc

13.71
0.605 (4.62%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Sage Therapeutics Inc SAGE NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.605 4.62% 13.71 23:00:08
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
13.46 13.45 13.97 13.94 13.105
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202405:30BWSage Therapeutics Announces First Quarter 2024 Financial..
17/4/202405:30BWSage Therapeutics Announces Topline Results from Phase 2..
11/4/202405:30BWSage Therapeutics to Report First Quarter 2024 Financial..
28/2/202405:30BWSage Therapeutics to Present at Upcoming March Investor..
21/2/202415:35EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
15/2/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:09EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14/2/202406:49EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/2/202406:20EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
14/2/202405:45EDGAR2Form 8-K - Current report
14/2/202405:30BWSage Therapeutics Announces Fourth Quarter and Full Year..
31/1/202416:25EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
31/1/202415:50EDGAR2Form 8-K - Current report
31/1/202405:30BWSage Therapeutics to Report Fourth Quarter and Full Year..
24/1/202415:10EDGAR2Form 8-K - Current report
23/1/202407:13EDGAR2Form SC TO-I - Tender offer statement by Issuer
08/1/202405:45EDGAR2Form 8-K - Current report
08/1/202405:32BWSage Therapeutics to Provide Business Updates at 42nd Annual..
08/1/202405:30BWSage Therapeutics Announces Changes to Board of Directors
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202405:30BWSage Therapeutics to Present at the 42nd Annual J.P. Morgan..
19/12/202307:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
19/12/202307:30EDGAR2Form DEF 14A - Other definitive proxy statements
14/12/202305:30BWZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for..
08/12/202308:00EDGAR2Form SC TO-C - Written communication relating to an issuer..
08/12/202307:30EDGAR2Form PRE 14A - Other preliminary proxy statements
08/11/202305:30BWSage Therapeutics to Present at Upcoming November Investor..
07/11/202306:39EDGAR2Form 8-K - Current report
07/11/202306:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/11/202306:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202305:46EDGAR2Form 8-K - Current report
07/11/202305:30BWSage Therapeutics Announces Third Quarter 2023 Financial..
24/10/202305:30BWSage Therapeutics to Report Third Quarter 2023 Financial..
18/10/202306:10DJNSage Therapeutics Gets FDA Orphan Designation for SAGE-718..
18/10/202305:30BWSage Therapeutics Announces U.S. Food and Drug..
06/9/202305:30BWSage Therapeutics to Present at Upcoming September Investor..
31/8/202305:45EDGAR2Form 8-K - Current report
31/8/202305:30BWSage Therapeutics Implements Strategic Reorganization to..
11/8/202307:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202306:51IHMARKETNEWSTuesday’s Wall Street Highlights: Novo Nordisk, RingCentral,..
07/8/202307:18DJNSage Therapeutics Shares Slide Premarket After Zurzuvae MDD..
07/8/202306:49EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/8/202306:26IHMARKETNEWSMonday’s Wall Street Highlights: Berkshire Hathaway, Tesla,..
07/8/202306:23DJNSage Therapeutics Mulls Job, Pipeline Cuts After FDA..
07/8/202305:45EDGAR2Form 8-K - Current report
07/8/202305:30BWSage Therapeutics Announces Second Quarter 2023 Financial..
04/8/202321:45BWSage Therapeutics to Host Business Update Webcast and..
04/8/202321:42BWFDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral..
05/6/202305:30BWSage Therapeutics to Present at the Goldman Sachs 44th..

Su Consulta Reciente

Delayed Upgrade Clock